Your browser doesn't support javascript.
loading
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.
Roederer, Mario; Keele, Brandon F; Schmidt, Stephen D; Mason, Rosemarie D; Welles, Hugh C; Fischer, Will; Labranche, Celia; Foulds, Kathryn E; Louder, Mark K; Yang, Zhi-Yong; Todd, John-Paul M; Buzby, Adam P; Mach, Linh V; Shen, Ling; Seaton, Kelly E; Ward, Brandy M; Bailer, Robert T; Gottardo, Raphael; Gu, Wenjuan; Ferrari, Guido; Alam, S Munir; Denny, Thomas N; Montefiori, David C; Tomaras, Georgia D; Korber, Bette T; Nason, Martha C; Seder, Robert A; Koup, Richard A; Letvin, Norman L; Rao, Srinivas S; Nabel, Gary J; Mascola, John R.
  • Roederer M; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Keele BF; SAIC-Frederick, Frederick National Laboratory, NIH, Frederick, Maryland 21702, USA.
  • Schmidt SD; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Mason RD; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Welles HC; 1] Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA [2] George Washington University, Washington DC 20052, USA.
  • Fischer W; Los Alamos National Laboratories, Los Alamos, New Mexico 87545, USA.
  • Labranche C; Department of Surgery, Duke University, Durham, North Carolina 27710, USA.
  • Foulds KE; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Louder MK; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Yang ZY; 1] Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA [2] Sanofi-Pasteur, Cambridge, Massachusetts 02139, USA.
  • Todd JP; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Buzby AP; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA.
  • Mach LV; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA.
  • Shen L; Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA.
  • Seaton KE; Human Vaccine Institute, Duke University, Durham, North Carolina 27710, USA.
  • Ward BM; Department of Surgery, Duke University, Durham, North Carolina 27710, USA.
  • Bailer RT; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Gottardo R; Fred Hutchison Cancer Research Center, Seattle, Washington 98109, USA.
  • Gu W; Biostatistics Research Branch, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Ferrari G; Department of Surgery, Duke University, Durham, North Carolina 27710, USA.
  • Alam SM; Human Vaccine Institute, Duke University, Durham, North Carolina 27710, USA.
  • Denny TN; Human Vaccine Institute, Duke University, Durham, North Carolina 27710, USA.
  • Montefiori DC; Department of Surgery, Duke University, Durham, North Carolina 27710, USA.
  • Tomaras GD; Human Vaccine Institute, Duke University, Durham, North Carolina 27710, USA.
  • Korber BT; Los Alamos National Laboratories, Los Alamos, New Mexico 87545, USA.
  • Nason MC; Biostatistics Research Branch, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Seder RA; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Koup RA; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Letvin NL; 1] Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02115, USA [2].
  • Rao SS; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
  • Nabel GJ; 1] Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA [2] Sanofi-Pasteur, Cambridge, Massachusetts 02139, USA.
  • Mascola JR; Vaccine Research Center, NIAID, NIH, Bethesda, Maryland 20892, USA.
Nature ; 505(7484): 502-8, 2014 Jan 23.
Article en En | MEDLINE | ID: mdl-24352234
ABSTRACT
A major challenge for the development of a highly effective AIDS vaccine is the identification of mechanisms of protective immunity. To address this question, we used a nonhuman primate challenge model with simian immunodeficiency virus (SIV). We show that antibodies to the SIV envelope are necessary and sufficient to prevent infection. Moreover, sequencing of viruses from breakthrough infections revealed selective pressure against neutralization-sensitive viruses; we identified a two-amino-acid signature that alters antigenicity and confers neutralization resistance. A similar signature confers resistance of human immunodeficiency virus (HIV)-1 to neutralization by monoclonal antibodies against variable regions 1 and 2 (V1V2), suggesting that SIV and HIV share a fundamental mechanism of immune escape from vaccine-elicited or naturally elicited antibodies. These analyses provide insight into the limited efficacy seen in HIV vaccine trials.
Asunto(s)

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Virus de la Inmunodeficiencia de los Simios / Vacunas contra el SIDA / Vacunas contra el SIDAS Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans / Male Idioma: En Año: 2014 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Infecciones por VIH / VIH-1 / Virus de la Inmunodeficiencia de los Simios / Vacunas contra el SIDA / Vacunas contra el SIDAS Tipo de estudio: Etiology_studies / Prognostic_studies / Risk_factors_studies Límite: Animals / Female / Humans / Male Idioma: En Año: 2014 Tipo del documento: Article